U.S. – Talk Bio

Sanofi Opens $130M ‘Flagship’ US Office Facility in Morristown, New Jersey

2 weeks ago talkbio0Tagged Corporate, flagship office, Health care facility, innovation, Market, Morristown, sanofi, U.S.

Sanofi; Morristown; flagship office; $130 million; healthcare; innovation; New Jersey; US market; corporate hub

Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US

2 weeks ago talkbio0Tagged Biological Science Disciplines, Biopharma, biopharma survey, biotech careers, Drug Industry, employment, Industry, Market, Transition Mutation, trends qualifier, U.S.

biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry

Pharma Companies Eye ‘First Sale’ Rule to Lessen Tariff Costs Amid New US Trade Measures

2 weeks ago talkbio0Tagged customs loophole, drug import duties, Drug Industry, first, minimis exemption, sale rule, tariff avoidance, trade compliance, Trump administration, U.S., US tariffs

first sale rule; pharmaceutical industry; US tariffs; customs loophole; drug import duties; tariff avoidance; trade compliance; Trump administration; de minimis exemption

Sanofi Announces $20 Billion US Investment Over Five Years

3 weeks ago talkbio0Tagged Big Pharma, development aspects, domestic partnerships, Drug Industry, Investments, Manufacturing, research, sanofi, Surgical construction, tariffs, U.S.

Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships

Sanofi Commits $20 Billion to US Expansion Amid Industry-Wide Investment Surge

3 weeks ago talkbio0Tagged drug production, Industry, Investments, pharmaceutical manufacturing, R&D, sanofi, supply chain, Surgical construction, trends qualifier, U.S.

Sanofi; US investment; pharmaceutical manufacturing; R&D; drug production; job creation; supply chain; industry trends

White House Threatens Most Favored Nation Plan to Lower US Drug Prices, but Many Questions Remain

4 weeks ago talkbio0Tagged Comparison, Drug Prescriptions, drug price, Favored, global price, Nation, Pharmaceutical Policy, Trump administration, U.S., White House

Most Favored Nation; drug pricing; White House; executive order; prescription drugs; Trump administration; US drug prices; global price comparison; pharmaceutical policy

Gilead tees up $11B in new US manufacturing, R&D investments

1 month ago talkbio0Tagged Billion, Investments, Manufacture, R&D, U.S., United States

United States, Investments, Manufacture, R&D, Billion, U.S.

From deal to disaster: Drugmakers face a changed Washington as Trump embraces most favored nation prices

1 month ago talkbio0Tagged Disasters, drugmakers, Medicaid, MFN, Nation, Policy, Prices, Transplant Registry Unified Management Program, U.S.

Prices, Transplant Registry Unified Management Program, MFN, Nation, Disasters, Medicaid, Policy, drugmakers, U.S.

‘Now is not the time to retreat’: BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge

1 month ago talkbio0Tagged Drug Industry, Health Care Reform, Home environment, Manufacturing, Myers, pharmaceutical manufacturing, pharmaceutical tariffs, squibb, Trump tariffs, U.S.

Bristol Myers Squibb, Trump tariffs, pharmaceutical manufacturing, domestic investment, pharmaceutical industry, US manufacturing, healthcare reform, pharmaceutical tariffs

Gilead, ‘closely attuned to’ potential US policy shifts, stands by long-acting PrEP launch

1 month ago talkbio0Tagged Gilead, HIV Prevention, launch, Lenacapavir, long-acting, Pre-Exposure Prophylaxis, U.S., United States Food and Drug Administration

Lenacapavir, Pre-Exposure Prophylaxis, United States Food and Drug Administration, launch, HIV prevention, long-acting, U.S., Gilead